The US government has filed a lawsuit against Regeneron, claiming that the company falsely inflated the average sales price for ophthalmology blockbuster Eylea to manipulate the Medicare reimbursement process.
The complaint contends that Regeneron submitted falsified average sales price reports to the Centres for Medicare and Medicaid Services (CMS) that excluded certain price concessions, such as reimbursing drug distributors for credit card processing fees.
